stockrow
Monday 9 November 2026
Export ICCM’s income statement to Excel — free account
IceCure Medical Ltd.
ICCMIceCure Medical Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $3.4 million, up 2.67% from fiscal 2024.
- Revenue
- −0.69%
- EPS
- −2,068.2%
- Free cash flow
- +3.88%
- Total debt
- −64.4%
Quarter to June 2026, against a year earlier
0.68
0.01
−1.45%
Follow ICCM
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 1 | 1 | 1 | 2 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | +20.6% | 4 | 9 | 22 | +87.3% | |
| Gross margin, % | 33.04 | 23.41 | 39.44 | 32.21 | 63.19 | 53.04 | 46.84 | 40.26 | 44.09 | 36.28 | 28.13 | +3.2 pt | ||||||
| EBT | (3) | (3) | (4) | (5) | (4) | (10) | (17) | (15) | (15) | (15) | (15) | +18.5% | ||||||
| EBT margin, % | (522.82) | (417.15) | (329.70) | (279.72) | (96.43) | (239.13) | (550.34) | (453.76) | (465.45) | (445.61) | (570.14) | +77.2 pt | ||||||
| Net income | (3) | 0 | (4) | (5) | (4) | (10) | (17) | (15) | (15) | (15) | (20) | +18.5% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.12 | 0.11 | 0.09 | 3.59 | 6.78 | 4.35 | 2.50 | 2.12 | 1.94 | 1.60 | 1.10 | +33.6% | |||||
| Earnings | (0.61) | (0.46) | (0.30) | (10.03) | (6.54) | (10.51) | (13.81) | (9.61) | (9.01) | (7.21) | (6.09) | +31.5% | ||||||
| Cash flow | (0.59) | (0.41) | (0.26) | (4.38) | (6.47) | (13.26) | (11.59) | (8.26) | (7.42) | (6.88) | 0.00 | +31.4% | ||||||
| Capex | 0.00 | 0.00 | 0.00 | (0.23) | (0.39) | (0.56) | (0.72) | (0.32) | (0.04) | (0.02) | 0.00 | n/m | ||||||
| Free cash flow | (0.59) | (0.41) | (0.26) | (4.61) | (6.86) | (13.82) | (12.32) | (8.57) | (7.46) | (6.90) | 0.00 | +31.4% | ||||||
| Book value | 0.40 | (0.04) | 0.29 | 7.26 | 9.90 | 28.36 | 20.62 | 8.00 | 4.07 | 4.28 | 0.00 | +30.2% | ||||||
| Shares, m | 5 | 6 | 12 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 13 | (9.7%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 25.36 | 697.14 | 311.69 | 455.31 | 19.09 | 12.98 | 0.62 | 152.2 | ||||||
| P/B | 0.00 | 0.00 | 0.00 | 187.39 | 25.07 | 106.21 | 61.97 | 130.53 | 7.44 | 3.88 | 0.14 | 52.2 | ||||||
| EV/Sales | 0.00 | 0.00 | 0.00 | 0.00 | 24.78 | 691.10 | 307.06 | 452.28 | 16.38 | 9.75 | (3.79) | 150.1 | ||||||
| EV/FCF | 0.00 | 0.00 | 0.00 | 0.00 | (16.38) | (216.03) | (54.65) | (62.25) | (1.84) | (1.06) | 0.50 | (35.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (3) | (3) | (3) | (2) | (4) | (13) | (14) | (13) | (13) | (15) | (21) | +18.6% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | (1) | (1) | 0 | 0 | 0 | 0 | +5.1% | ||||||
| Free cash flow | (3) | (3) | (3) | (2) | (4) | (13) | (15) | (13) | (13) | (15) | (21) | +18.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 3 | 0 | 4 | 3 | 6 | 26 | 24 | 10 | 5 | 8 | 11 | +12.6% | |||||
| Net debt | (3) | (1) | (4) | (6) | (3) | (25) | (24) | (11) | (7) | (9) | (12) | +13.6% | ||||||
| Shareholders’ equity | 2 | 0 | 3 | 3 | 6 | 27 | 25 | 12 | 7 | 9 | 12 | +17.6% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (124.73) | (173.60) | (82.59) | (72.51) | (42.59) | (46.54) | (54.36) | (62.89) | (105.69) | (113.79) | 0.00 | +10.9 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | (114.34) | (300.57) | (551.50) | (659.11) | 0.00 | (5,648.95) | 0.00 | (5,648.9) pt | ||||||
| ROE | (354.30) | (311.54) | (227.23) | (136.41) | (83.45) | (60.69) | (64.83) | (77.97) | (160.70) | (188.78) | 0.00 | +165.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 60 | 64 | 46 | 78 | 66 | 69 | — | +2.8% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.06 | 0.07 | 0.04 | 0.05 | 0.05 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026
IceCure Medical Ltd. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AMIX Autonomix Medical, Inc. | $3.0M | — (loss-making) | — | — | n/m | −36.10% (below 0%: shrinking) | — | 0.00% | Compare |
| BJDX Bluejay Diagnostics, Inc. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | +20.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| AIDX 20/20 Biolabs Inc. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | −23.98% (below 0%: shrinking) | 41.71% | (170.30%) | Compare |
| IVF INVO Fertility, Inc | $2.6M | — (loss-making) | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | Compare |
| NUWE Nuwellis, Inc. | $2.5M | — (loss-making) | — (loss-making) | +14.14% (above 0%: growing) | n/m | −51.55% (below 0%: shrinking) | 76.08% | (160.94%) | Compare |
| CODX Co-Diagnostics, Inc. | $2.4M | — (loss-making) | — (loss-making) | +1.96% (above 0%: growing) | n/m | +17.47% (above 0%: growing) | 72.73% | (3,733.17%) | Compare |
| ICCM IceCure Medical Ltd. | $2.3M | — (loss-making) | — (loss-making) | −0.69% (below 0%: shrinking) | n/m | +3.88% (above 0%: growing) | 32.38% | (466.19%) | |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | — (loss-making) | — | — | n/m | −1.05% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ADGM Adagio Medical Holdings, Inc. | $1.8M | — (loss-making) | — | −33.50% (below 0%: shrinking) | n/m | −12.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $2.5M | — | — | +8.05% | — | −6.95% | 35.06% | (29.64%) |